Search results
View Jerry McMahon’s profile on LinkedIn, a professional community of 1 billion members. Dr. McMahon brings more than 30 years of exceptional biotechnology leadership, scientific…
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
7 de sept. de 2022 · STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
26 de oct. de 2021 · Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer. Scott Myers, Current Member of Harpoon’s Board of Directors Named Chair, Replacing Ron Hunt...
7 de sept. de 2022 · McMahon has held scientific, pharmaceutical and venture capital positions and has been the CEO or President of multiple biotechnology companies leading novel therapeutic programs from discovery and development to drug approvals for internal and in-licensed products.
7 de sept. de 2022 · STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer. Sep 07, 2022, 03:00 ET. Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of...
As announced by Harpoon Therapeutics Inc. in a news release and in a regulatory filing published on Tuesday, October 26, 2021, Gerald (Jerry) McMahon leaves his post as chief executive officer at the clinical-stage immunotherapy company, after about five years in the role, effective immediately.
